Search
Travere Therapeutics Inc
TVTXAdd to Watchlist
52.750USD
-0.520-0.98%
Market hours 10/15, 14:34（ET）
4.91BMarket Cap
LossP/E TTM
Travere Therapeutics Inc (TVTX) Stock Price Target & Forecast
Analyst Rating
Based on 15 analysts giving stock ratings to Travere Therapeutics Inc in the past month.
Buy
6 Strong Buy
8 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
74.077USD+42.11%
TVTX Analyst Recommendation Trends
In the current month, TVTX has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TVTX average Analyst price target in the last month is 74.077.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
6
6
6
6
6
6
6
6
8
8
8
8
8
8
7
7
1
1
1
1
1
1
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15
15
15
15
15
15
15
15
TVTX Analyst Rating for Peer Comparison
Updated: Oct 14, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Revolution Medicines Inc
RVMD
9
14
1
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
7
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Financial Forecasting
Based on analysts' estimates, TVTX EPS is projected to reach 0.061 in FY2026Q3, following reported EPS of -0.372 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.12
-0.27
-0.14
0.06
0.42
Actual
0.03
-0.40
-0.37
--
--
Surprise
+125.61%
-52.08%
-168.28%
--
--
FAQs
What is Travere Therapeutics Inc's expected revenue for the next quarter?
Travere Therapeutics Inc's expected revenue is 195.68M.
What is Travere Therapeutics Inc's price target?
Analysts forecast that Travere Therapeutics Inc's price target is USD 74.08, with the highest forecast at USD 89.00 and the lowest forecast at USD 62.00.
How have Travere Therapeutics IncTVTX's recent earnings per share performed?
The market expectation was USD -0.37, while Travere Therapeutics IncTVTX's earnings per share (EPS) for the previous quarter was USD -0.40. EPS for the next quarter is expected at USD 0.06.
What is the analyst rating for Travere Therapeutics Inc?
Based on the ratings of Travere Therapeutics Inc's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.